Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Below 50-Day Moving Average – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.80 and traded as low as $6.31. Capricor Therapeutics shares last traded at $6.37, with a volume of 548,281 shares.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Jones Trading lowered their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Roth Capital reduced their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, July 14th. B. Riley initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.25.

Capricor Therapeutics Stock Down 0.5%

The stock’s 50-day simple moving average is $6.80 and its two-hundred day simple moving average is $8.77. The company has a market capitalization of $291.22 million, a price-to-earnings ratio of -3.88 and a beta of 0.68.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $28,000. Tower Research Capital LLC TRC raised its position in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at about $95,000. Sheets Smith Investment Management acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $107,000. Finally, KLP Kapitalforvaltning AS raised its position in shares of Capricor Therapeutics by 65.2% in the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 4,300 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.